EGFR and non-small cell lung carcinoma: Likewise, KEYNOTE-789 found that adding pembrolizumab to pemetrexed-platinum did not significantly improve PFS or OS vs. placebo in EGFR-mutant advanced NSCLC progressing on EGFR TKIs (PFS HR 0.80, 95% CI 0.65–0.97; OS HR 0.84, 95% CI, 0.69–1.02) [125].